Results 221 to 230 of about 4,544,497 (292)

The protein corona at the nano-bio interface: the need for standardized methodology and opportunities for neurodegenerative disease intervention. [PDF]

open access: yesRSC Adv
Shitaye G   +11 more
europepmc   +1 more source

hERG1 channels and potential therapeutics for long QT syndrome

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend Prolonged QT results from hERG1 channel dysfunction. (A) Physiological anterograde trafficking of hERG1 channels to the plasma membrane, leading to a normal electrocardiogram. (B) Prolonged QT results from the presence of fewer hERG1 channels on the plasma membrane due to decreased anterograde trafficking or reduced function due ...
Elizabeth H. Schneider   +3 more
wiley   +1 more source

The OCEANIC trial journey: from failure to breakthrough? [PDF]

open access: yesEur Heart J Cardiovasc Pharmacother
Caso V, Ten Cate H, van Gelder IC.
europepmc   +1 more source

Inhibitory Activity of Red Panda Islet Amyloid Polypeptide on Human IAPP Aggregation

open access: yesJournal of Peptide Science, Volume 32, Issue 12, December 2026.
The figure shows the comparison of (a) human islet amyloid polypeptide (hIAPP) self‐assembling into a fibril structure and (b) a model of hIAPP self‐assembling in the presence of red panda islet amyloid polypeptide (IAPP). The figure was produced from PDB file 6Y1A using Swiss PDB viewer software.
Lauren Phillips   +5 more
wiley   +1 more source

Nerve Growth Factor is Sufficient to Cause Multiple Osteoarthritis‐Relevant Pathologic Features in Naïve Murine Knee Joints

open access: yesArthritis &Rheumatology, Volume 78, Issue 11, Page 2246-2260, November 2026.
Objective Nerve growth factor (NGF), a key mediator of pain, is increased in osteoarthritic (OA) joints. Antibodies against NGF show analgesic effects in painful knee OA, but clinical development was stopped because of side effects in the joints. Knowledge about the biologic effects of NGF on joint tissues is limited. Therefore, we explored the effects
Alia M. Obeidat   +14 more
wiley   +1 more source

New therapeutic options for metabolic‐associated steatotic liver disease

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 11, Page 3770-3777, November 2026.
An increasing number of patients are being diagnosed with metabolic dysfunction‐associated steatotic liver disease (MASLD). MASLD results from disturbances in hepatic lipid metabolism and is associated with an increased risk of cirrhosis and hepatocellular carcinoma and significant extrahepatic morbidity, including cardiovascular disease and ...
Tessa Straatmijer, Midas Mulder
wiley   +1 more source

Home - About - Disclaimer - Privacy